Results 281 to 290 of about 109,434 (328)

Management of von Willebrand Disease With a Factor VIII‐Poor von Willebrand Factor Concentrate: Results From the Paediatric Cohort of a Prospective Observational Post‐Marketing Study

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Although clinical experience of a triple‐secured, plasma‐derived, von Willebrand factor (pdVWF), almost devoid of Factor VIII (FVIII) in adults with von Willebrand disease (VWD), is widely reported, its use in children is less documented.
Jenny Goudemand   +10 more
wiley   +1 more source

A Thermosensitive Gel Containing Biodegradable Nanoparticles Carrying Calcium Hydroxide as Antibacterial Intracanal Therapy

open access: yesInternational Endodontic Journal, EarlyView.
ABSTRACT Aim To characterise and evaluate mucoadhesive strength and antibacterial properties of a nanotechnological formulation for endodontic disinfection based on biodegradable nanoparticles dispersed in a thermosensitive gel containing calcium hydroxide (Ca(OH)2‐NPs‐gel).
Xavier Roig‐Soriano   +9 more
wiley   +1 more source

You Can’t Hold Their Hand the Whole Time: A Qualitative Study of Parents’ Experiences of Adolescents With Food Allergy

open access: yesJournal of Advanced Nursing, EarlyView.
ABSTRACT Aims To explore parents’ experiences of parenting adolescents with food allergies. Design An interpretive descriptive qualitative study. Methods Semi‐structured interviews were conducted between November 2023 and March 2024 with 11 parents of adolescents with food allergies aged 12–16 years, 8 mothers and 3 fathers. Reflexive thematic analysis
Meg O’ Sullivan   +4 more
wiley   +1 more source

Allergy by Proxy to Penicillins Presenting as Recurrent Idiopathic Anaphylaxis Within the Household: A Case Report

open access: yes
Contact Dermatitis, EarlyView.
Adrien Bénic   +3 more
wiley   +1 more source

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin   +24 more
wiley   +1 more source

Taurolidine-induced Severe Anaphylaxis. [PDF]

open access: yesKidney Med
Horvath LC   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy